Print

Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer

https://www.facingourrisk.org/XRAY/trodelvy-metastatic-triple-negative-breast-cancer
Full article: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/ascent-a-randomized-phase-iii-study-of-sacituzumab-govitecan-sg-vs-treatment-of-physician-s-choice-tpc-in-patients-pts-with-previously-treat

The ASCENT study confirmed an earlier study and showed that the drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at new treatments for people with metastatic TNBC.  

A number of other clinical trials for treating patients with metastatic TNBC can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 

 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.